GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹2,681 Cr | ₹1,270 Cr | ₹2,804 Cr | ₹3,033 Cr | ₹2,280 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
Year | Total Non-Current Liabilities |
---|---|
Mar2023 | ₹2,681 Cr |
Mar2022 | ₹1,270 Cr |
Mar2021 | ₹2,804 Cr |
Mar2020 | ₹3,033 Cr |
Mar2019 | ₹2,280 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹2,681 Cr | 111.16 | |
Mar2022 | ₹1,270 Cr | -54.72 | |
Mar2021 | ₹2,804 Cr | -7.56 | |
Mar2020 | ₹3,033 Cr | 33.03 | |
Mar2019 | ₹2,280 Cr | - |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹29,743.9 Cr | -2.4% | 7.4% | 88% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹361,916.0 Cr | 0.3% | -7.5% | 53.9% | Stock Analytics | |
CIPLA | ₹115,034.0 Cr | 1.1% | -4.8% | 56.4% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹105,929.0 Cr | 1.6% | 1.6% | 27.6% | Stock Analytics | |
DIVIS LABORATORIES | ₹104,873.0 Cr | -1.9% | 10.7% | 21.4% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,322.0 Cr | 5.2% | -0.2% | 90.1% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | -2.4% |
7.4% |
88% |
SENSEX | -0.6% |
0.3% |
21.8% |
You may also like the below Video Courses